1. Home
  2. BNBX vs REVB Comparison

BNBX vs REVB Comparison

Compare BNBX & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BNBX

Applied DNA Sciences Inc.

N/A

Current Price

$0.53

Market Cap

3.7M

ML Signal

N/A

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

N/A

Current Price

$0.98

Market Cap

4.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BNBX
REVB
Founded
1983
2020
Country
United States
United States
Employees
26
9
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7M
4.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BNBX
REVB
Price
$0.53
$0.98
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
190.6K
45.9K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$253.12
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.35
$0.47
52 Week High
$6.17
$3.21

Technical Indicators

Market Signals
Indicator
BNBX
REVB
Relative Strength Index (RSI) 55.74 38.03
Support Level $0.45 $0.85
Resistance Level $0.61 $1.20
Average True Range (ATR) 0.06 0.05
MACD 0.02 -0.00
Stochastic Oscillator 67.41 1.07

Price Performance

Historical Comparison
BNBX
REVB

About BNBX Applied DNA Sciences Inc.

BNB Plus Corp focuses on digital asset treasury management of BNB. The group is unlocking institutional-grade access to the Binance ecosystem, delivering non-directional yield strategies and long BNB exposure, powering the future of blockchain through a transparent, actively managed BNB treasury. The Company's differentiated blends sophisticated DeFi yield generation with Binance-native opportunities, unlocking access to high-performance digital assets for investors traditionally excluded from the space.

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.

Share on Social Networks: